
PFAS Bioaccumulation in Vertebrates: A Very Brief Overview

Tyler Hoskins, Ph.D.

Dept. of Forestry and Natural Resources & The Institute for a Sustainable Future Purdue University




Scan to Connect with the PFAS Strategic Research Team at Purdue!




PFAS Are Structurally Diverse: So Are Their Bioaccumulation Potentials

- Bioaccumulation is the process of chemical accumulation in an organism over time
 - Central concept in toxicology and risk assessment
- PFAS are diverse. We know a lot about bioaccumulation for two classes:
 - Perfluorocarboxylic acids (PFCAs, e.g., PFOA)
 - Perfluorosulfonic acids (PFSAs, e.g., PFOS)
- 14,000+ PFAS in other classes not as well studied
 - Some precursors have high bioaccumulation potential
 - Harder to study: can biotransform!
 - Terminal degradation products are usually PFSAs and PFCAs that cannot degrade further






Structure Correlates with Bioaccumulation



Breaking the Rules: PFAS Bioaccumulation is Protein-Mediated

- Historically, persistent pollutants (think DDT, other PCBs, Dioxins) partition to fatty tissues
 - Lipids are so important to bioaccumulation potential that we often normalize to lipid content for these chemicals
- PFAS interact strongly with proteins of all kinds, especially carrier proteins
 - Examples: albumins, hemoglobins, myoglobins, liver-type fatty acid binding proteins (LFAB-Ps), transthyretins, many others
 - Increasing protein concentrations associated with increased [PFAS]!




Note the positive relationships between PFOS and serum proteins for bovine albumin and 3 fish

From Point et al., (2023): https://doi.org/10.1016/j.scitotenv.2 023.162337

Breaking the Rules: PFAS Bioaccumulation is Protein-Mediated

- Bioaccumulative PFAS partition preferentially to protein-rich tissues
 - Blood, liver, lung are primary compartments. Less but still significant accumulation in other organs including muscle.
 - Can cross blood-brain barrier
- High variability in accumulation across species and sexes
 - Factors driving variability not yet understood




PFAS profiles differ dramatically across tissues in humans. From Pérez et al., (2013): <u>https://doi.org/10.1016/j.envint.2013.06.004</u>

Elimination Can Be Slow...

But reducing exposure does reduce burdens over time!


PFAS	Human Male	Human Female
PFOA	2.3 – 3.8 y	2.3 – 3.8 y
PFOS	3.4 - 5.4 y	3.4 – 5.4 y
PFHxS	5.3 - 8.5 y	5.3 - 8.5 y
PFHxA	32 d	NA



Elimination half-times for 4 common PFAS

Human serum concentrations over time, from National Health & Nutrition Examination Survey (NHANES)

Final Caveat: Bioaccumulation *f* Toxicity



Larval GenX exposure reduces terrestrial growth in gray treefrogs. From Barragan et al., (2023): https://doi.org/10.1021/acs.est.3c03191



Institute for a Sustainable Future

-Although higher tissue burdens <u>usually</u> lead to more toxicity, assuming that bioaccumulation potential <u>always</u> predicts toxicity is not advisable.

-Example:

-Hexafluoropropylene dimer acid (HFPO-DA, aka "GenX") is less bioaccumulative than what it replaced (PFOA)

-Emerging evidence that GenX can often be more toxic than PFOA

-Example: Barragan et al., (2023) found that larval exposure to GenX reduced gray treefrog growth after metamorphosis, while PFOA did not




Indiana PFAS Assessment 1.0

- Purdue's Institute for a Sustainable Future is sponsoring a report on the state of knowledge around PFAS in our state
- Broad focus: sources, fate/transport, ecological effects, human health effects, mitigation options, current regulatory landscape, socioeconomic impacts and more
- Input from PFAS experts across multiple academic institutions and state agencies
- Targeted at non-experts including the public and policymakers
- Expect release in late fall 2024: keep an eye out!



Thank You

Contact Me: tdhoskin@purdue.edu



Scan to Connect with the PFAS Strategic Research Team at Purdue!

